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INVESTIGATING THE ATTITUDES AND PERCEPTIONS OF PHARMACY 
TECHNICIANS IN THE DISPENSING OF NALOXONE IN PHARMACIES 
ACROSS MASSACHUSETTS  
SHAWN KURIAN 
ABSTRACT 
 The number of opioid-related overdose deaths in the United States has quadrupled 
since 1999. For this reason, in October 2017 President Donald Trump declared the opioid 
epidemic a public health emergency. Massachusetts is particularly affected by the opioid 
epidemic as evident in an opioid-related death rate that is double the national rate. 
Naloxone is a prescription medication that works antagonistically to bind opioid receptors 
and rapidly reverses and blocks the effects of opioids. This drug is widely used to revive 
patients who are experiencing an opioid overdose. Prior research on the topic of attitudes 
toward naloxone prescriptions and dispensing has focused primarily on three groups of 
people: patients, prescribers, and pharmacists. However, in recent years there has been an 
expansion of the role of the pharmacy technician in healthcare administration, such as in 
the administration of vaccines. Thus, there is a lack of research centered on the role of 
pharmacy technicians in the dispensing of naloxone.  
The aim of this study was to investigate the attitudes and perceptions of pharmacy 
technicians in the dispensing of naloxone across Massachusetts. This goal was 
accomplished by purposively sampling CVS pharmacies in 13 municipalities across the 
state, with 7 municipalities having an opioid-related death rate per 100,000 people greater 
than the state average and 6 municipalities having an opioid-related death rate per 100,000 
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people less than the state average. These municipalities were termed High-Risk 
Municipalities and Low-Risk Municipalities, respectively. Three CVS pharmacies were 
sampled within each municipality, yielding a total sample size of 39 CVS pharmacies with 
21 from High-Risk Municipalities and 18 from Low-Risk Municipalities. Pharmacy 
technicians working in each pharmacy were administered a survey pertaining to their 
attitudes and perceptions on naloxone dispensing.  
The results of this study demonstrated that there was a significant difference 
between technicians working in High-Risk Municipalities and Low-Risk Municipalities 
regarding the percentage of patients who they believed could benefit from naloxone. 
Specifically, 67% of participants in Low-Risk Municipalities indicated that less than 25% 
of patients could benefit from having a naloxone kit available whereas 67% of participants 
in High-Risk Municipalities indicated that greater than 50% of patients could benefit 
(Mann-Whitney U significance level = 0.001). This result is critical, especially considering 
the fact that there was no significant difference between both groups of technicians on their 
perceptions of patients who used illicit opioids or prescription opioids. In addition, 
unsolicited feedback from participants revealed several common themes among 
technicians working in both groups, including the belief that patients could benefit from a 
reduced cost of naloxone and that both technicians and patients may be unaware that 
naloxone can benefit individuals taking prescription opioids rather than just people who 
inject drugs.  
Future studies could investigate whether participant characteristics, such as years 
of experience working in the pharmacy may have influenced the results. Also, future 
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research could be directed toward determining if there might be a relationship between 
syringe sales and naloxone sales in High-Risk Municipalities.  
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 1 
INTRODUCTION 
 
 In modern society, individuals are faced with a wide array of medical ailments that 
require the use of analgesic drugs to achieve relief from pain. One major class of analgesic 
drugs is opioids, a group of pain-relieving drugs which are commonly prescribed to 
individuals across the globe. It was in 1806 when a German pharmacist by the name of 
Friedrich Sertürner successfully isolated morphine from the opium poppy, and thus paved 
the way for the application of morphine and other opioids in clinical practice (Pathan & 
Williams, 2012).  
 Morphine and other synthetic and semi-synthetic opioids such as fentanyl, 
dihydrocodeine, buprenorphine, and oxycodone achieve analgesic effects through receptor 
binding and subsequent activation of intracellular cascades. These effects are mediated by 
the G-protein-coupled opioid receptors MOP, DOP, KOP, and NOP. When an opioid 
agonist binds to one of these receptors, it triggers a series of intracellular changes whereby 
the Gα subunit exchanges its bound guanosine diphosphate with guanosine triphosphate. 
Following this, the Gα and Gβγ subunits dissociate from one another and the Gβγ subunit 
goes on to cause hyperpolarization of the cell by opening the G-protein-coupled inwardly-
rectifying potassium channel, Kir3, thereby allowing potassium ions to flow into the cell 
(Zylbergold, Ramakrishnan, & Hebert, 2010). On the other hand, the Gα subunit goes on 
to inhibit adenylyl cyclase, thus reducing the levels of cyclic adenosine monophosphate-
dependent calcium influx within the cell. All in all, the final result is cell hyperpolarization, 
a reduction in calcium ion movement, and a reduction in neurotransmitter release (Al-
Hasani & Bruchas, 2011; Pathan & Williams, 2012).    
 2 
Normally, pain results in greater activity of primary sensory neurons which go on 
to release substance P and glutamate in the dorsal horn of the spinal cord. In general, it is 
believed that opioids exert their analgesic effects by inhibiting this neurotransmitter release 
from these afferent terminals in the spinal cord (Chahl, 1996; White & Irvine, 1999). 
 Despite the fact that opioids are commonly used in the treatment of both acute and 
chronic pain, there are several side effects associated with their use including constipation, 
nausea, vomiting, respiratory depression, and sedation. It has also been noted that opioid-
induced hormonal changes may take place, resulting in lower levels of testosterone in 
males and estrogen in females. The clinical side effects of this include depression and loss 
of sexual activity (Benyamin et al., 2008). Moreover, opioid use has also been linked to 
sleep disturbances. For instance, in a study conducted by Dimsdale et al. (2007) it was 
observed that opioid use significantly reduced the amount of time spent in stages three and 
four of the sleep cycle (deep sleep) and increased the amount of time spent in stage two 
(light sleep) (Dimsdale, Norman, DeJardin, & Wallace, 2007).  
Furthermore, continued use of opioids results in their tolerance—a loss of 
biological effectiveness requiring patients to take increasingly higher doses to achieve the 
same effects. Evidently, these higher dosages may further exacerbate the unwanted side 
effects previously mentioned. This may result from changes in gene expression and 
adenylyl cyclase, as well as uncoupling of G-proteins (Al-Hasani & Bruchas, 2011; White 
& Irvine, 1999). Tolerance is also significantly enhanced in response to familiar cues; for 
example, the same environment. Thus individuals who consume/inject drugs may be at 
greater risk of overdose if they use the same dosage in a new environment (White & Irvine, 
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1999). Therefore, in addition to exacerbating the negative side effects already mentioned, 
the continued use of opioids can result in tolerance and increased risk of overdose. In 
general, opioid overdose is primarily a result of extensive respiratory depression due to a 
reduction in neurotransmission, and this condition leads to a decreased sensitivity to 
oxygen and carbon dioxide levels, thus resulting in a reduced respiratory rate, hypoxia, and 
potentially death (White & Irvine, 1999). Factors that may increase one’s risk of an 
overdose include the following: use of multiple opioids; increased tolerance to opioids 
(individuals take higher doses to achieve the same effects); periods of time without using 
opioids, such as incarceration or hospitalization, which may result in lower tolerance 
(individuals take the same high dose as before); previous history of overdose; and any 
opioid prescription with alcohol or benzodiazepine use (Bailey & Wermeling, 2014; Green, 
Ray, Bowman, McKenzie, & Rich, 2014; Lim, Bratberg, Davis, Green, & Walley, 2016).   
The Opioid Epidemic in the United States 
In the United States, the increased use and misuse of opioids stem from an issue 
that took place in the late 1990s. During this time period, pharmaceutical companies 
employed unfair and, subsequently determined, deceiving marketing measures, which 
included attempts to ensure physicians that patients would not become addicted to opioids. 
As a result, physicians were more willing to prescribe them to patients (U.S. Department 
of Health and Human Services, 2018). In addition to prescribing a greater number of 
opioids during this time, physicians were prescribing them under conditions that are now 
known to be harmful and precursors for misuse, addiction, and overdose. These conditions 
include prescribing high doses of opioids for prolonged periods of time (Volkow, Doherty, 
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Gottlieb, McCance-Katz, & Schuchat, 2017). Consequently, the use of prescription opioids 
has increased tremendously since then, but so too have the consequences of this over-
exposure. For example, in 2016 the number of opioid-related overdose deaths was more 
than four times greater than the number of opioid-related overdose deaths in 1999. Put 
differently, it is estimated that approximately 115 Americans die each day from an opioid 
overdose (Rudd, Seth, David, & Scholl, 2016).  
The aforementioned statistics do not solely pertain to overdose deaths from 
prescription opioids, but rather from any opioid, including illicit opioids such as heroin and 
street fentanyl. In light of this, there is evidence to believe that the increased use of 
prescription opioids has resulted in a similar increase in illicit opioid use. Specifically, a 
study conducted in 2015 demonstrated that individuals who reported being hooked on 
prescription opioids before their first injection of heroin were more likely to inject one or 
more times per day than those who were not hooked (Al-Tayyib, Koester, & Riggs, 2017). 
This provides support for the theory that prescription opioids may act as a gateway for the 
use of illicit opioids, especially considering they produce similar neuropharmacological 
effects. As previously mentioned, individuals who become tolerant to prescription opioids 
may no longer observe their desired effects with the regular dose. Since heroin and fentanyl 
have a higher potency than most commonly prescribed prescription opioids, these 
individuals might use these illicit opioids in an attempt to observe similar pharmacological 
effects quicker and more intensely than their prescription opioids (National Academies of 
Sciences, Engineering, and Medicine, 2017).  
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Another factor influencing an individual’s decision to switch from prescription 
opioids to opioids such as heroin and street fentanyl is the price. For illicit use, prescription 
opioids must first be diverted from a lawful source and then sold illegally, thereby driving 
up costs. On the other hand, because opioids such as heroin and street fentanyl are sold 
directly in well-organized, street markets with strong infrastructure, the costs can be kept 
relatively low (National Academies of Sciences, Engineering, and Medicine, 2017). 
Consequently, with lower costs and easier access compared with prescription opioids, it is 
not surprising that the use of heroin and street fentanyl is on the rise. Therefore, in recent 
years there has been a key shift from prescription opioids to illicit opioids. Figure 1 depicts 
these trends by illustrating the increasing number of opioid-related overdose deaths (per 
100,000 people) from 2000 to 2015, and the contribution by type of opioid involved in the 
overdose. From this figure, it is evident that in recent years there has been a sharp increase 
in heroin- and fentanyl-related overdose deaths, which contributed to the increasing 
overdose death rated due to any opioid, whereas the contribution from commonly 
prescribed opioids remains relatively constant.  
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Figure 1. Overdose deaths involving opioids in the United States (2000-2015). This 
graph shows the number of opioid-related overdose deaths per 100,000 people from 2000 
to 2015, subdivided into any opioid, commonly prescribed opioids, heroin, and other 
synthetic opioids including fentanyl. Taken from (Centers for Disease Control and 
Prevention, 2017).  
 
Not surprisingly, the opioid epidemic in America has gained much attention in 
recent years. In October 2017, President Donald Trump declared the opioid epidemic a 
public health emergency (Wilkie, 2017). However, this issue has not met with the same 
degree of urgency across the country. Certain states are faced with a much greater burden 
of opioid-related overdose deaths and have experienced substantially worse shifts in 
mortality over the past 35 years. As Figure 2 shows, there is immense variability of opioid 
overdose deaths between states as well as within each state.   
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Figure 2. A geographical spread of unintentional opioid overdose deaths, by county, 
from 1979 to 2015. This figure shows the increasing number of opioid overdose deaths 
across the United States over the years, as well as the specific regions which are more 
heavily affected. Taken from (United States Joint Economic Committee, 2017). 
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The Opioid Epidemic in Massachusetts 
The Commonwealth of Massachusetts has seen a marked increase in the opioid-
related death rate over the past decade. In recent years, the opioid-related death rate per 
100,000 people in Massachusetts has shockingly doubled compared with the rate for the 
United States as a whole (Figure 3). Furthermore, similar to other states, no city or town is 
unaffected by the opioid crisis (Massachusetts Department of Public Health, n.d.). Driven 
by the disease of addiction, some Massachusetts residents may be transitioning from using 
prescription opioids legally to using opioids illegally, whether through diverted 
prescription medications or illicitly manufactured fentanyl and heroin. In particular, 
Massachusetts has seen a striking increase in the illicit use of fentanyl in the past few years 
(Figure 4). For example, there was an increased proportion of opioid-related overdose 
deaths due to fentanyl from 32% in 2013 to 74% in the first half of 2016. It is believed that 
a vast majority of these deaths are from illicitly manufactured fentanyl rather than diverted 
prescription fentanyl, potentially owing to reduced costs and ease of access through the 
street-market infrastructure (Somerville et al., 2017).  
Despite these statistics, the Massachusetts state government has taken the initiative 
to combat this opioid epidemic. Most notably, in 2015 Governor Charlie Baker signed into 
law Chapter 55 of the Acts of 2015, which allows various government agencies to utilize 
datasets in order to take a detailed and far-reaching look at the opioid epidemic in the state. 
The resulting report painted a clear picture of the various demographics affected by the 
epidemic as well as the much-needed steps for the future. Moreover, in 2016 Governor 
Baker signed a law that restricts the first-time opioid prescriptions for adults to a 7-day 
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supply and any opioids prescribed for minors to a 7-day supply (Massachusetts Department 
of Public Health, n.d.; National Academies of Sciences, Engineering, and Medicine, 2017). 
Both of these efforts help to mitigate the chronic use of opioids by Massachusetts residents, 
and as a result, they can help prevent individuals from falling victim to the disease of 
addiction.  
 
 
Figure 3. A comparison of the age-adjusted opioid-related death rate per 100,000 
people in Massachusetts and the United States overall. This figure shows that in recent 
years there has been an unprecedented increase in the opioid-related death rate in 
Massachusetts compared with the United States as a whole. Taken from (Massachusetts 
Department of Public Health, n.d.).  
 10 
 
Figure 4. Percentage of opioid deaths in Massachusetts (2014-2017) with specific 
drugs present. This figure shows that in recent years illicit opioids, particularly fentanyl, 
have been present in a greater percentage of opioid deaths compared with prescription 
opioids. Taken from (Massachusetts Department of Public Health, 2017).  
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Responding to an Overdose: Naloxone  
Naloxone, often sold under the brand names Narcan (Adapt Pharma, Inc.; Radnor, 
PA) and Evzio (Kaleo Pharma; Richmond, VA), is an opioid antagonist that is currently 
available as a prescription medication. Through advocacy by public health and community 
members, both the availability and accessibility of naloxone for use by laypersons have 
greatly expanded over the past two decades. Indeed, laws in most states (by the same 
standing order mechanism) permit access to naloxone through community-based 
organizations and community pharmacies without having to see a prescriber first for a 
prescription. Pharmacy naloxone access began in neighboring Rhode Island and quickly 
spread as a policy innovation to Massachusetts and  41 states across the United States (CVS 
Pharmacy, 2018). In general, the provision of naloxone has proved to have a positive 
impact on overdose prevention. A study by Walley et al. (2013) demonstrated this effect 
by analyzing data collected from 2002 to 2009. They found that Massachusetts 
communities receiving overdose education and nasal naloxone kits during this time frame 
had reduced rates of opioid-related overdoses compared with communities having no 
implementation of education and naloxone (Walley et al., 2013). This study provides 
evidence for the notion that overdose education and the provision of naloxone are a 
successful intervention for tackling the opioid epidemic in Massachusetts.  
Although the exact mechanism of action of naloxone is not completely understood, 
it is believed that the medication competes antagonistically with opioids at their MOP, 
DOP, and KOP receptors, having the greatest affinity for the MOP receptor. By binding to 
these receptors, naloxone is able to rapidly reverse (within several minutes) and block the 
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effects of opioids. The safety profile of naloxone reveals that it exhibits virtually no 
pharmacological activity if opioids are not present in the body. Furthermore, high doses of 
naloxone cannot result in an overdose, and it is not possible for one to feel any euphoric 
effects after taking naloxone. Therefore, the chance of misusing this drug for recreational 
purposes and subsequently becoming addicted is minimal. Moreover, naloxone has been 
shown to exhibit no adverse effects in reproducing animal models, and it has been approved 
for use in children. The only adverse effect reported from naloxone use is that it may cause 
precipitated withdrawal in individuals who are opioid-dependent. Though this is not life-
threatening, these individuals may experience symptoms such as tachycardia, fever, high 
blood pressure, nausea, and vomiting. However, this has been shown to last for only 30 to 
60 minutes because of the short half-life of the drug. Furthermore, withdrawal symptoms 
have been shown to increase with increasing dose of naloxone and are related to the extent 
of the individual’s opioid dependency (Adapt Pharma Inc., 2015; Wermeling, 2015).   
Typically, naloxone is not dispensed for oral consumption because most of the drug 
becomes inactive after undergoing liver metabolism. Consequently, it is currently approved 
for administration through four main methods: intravenous, intramuscular, subcutaneous, 
and intranasal (Rzasa Lynn & Galinkin, 2018; U.S. Deparment of Health & Human 
Services, 2017).   
Although naloxone is the medication indicated for reversing opioid overdose, there 
are case reports of some naloxone-containing medications and other drugs available for 
managing opioid dependence that have been used for overdose reversal. For instance, 
buprenorphine is a semi-synthetic opioid that was first marketed in the United States as an 
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opioid analgesic, yet this drug is now well known for its potential use as a partial agonist 
in the treatment of opioid dependence. Similar to naloxone, buprenorphine binds to the 
MOP receptor with high affinity and displaces/prevents binding of other opioids. Suboxone 
(Reckitt Benckiser; Slough, United Kingdom), a prescription medication that is currently 
available in the United States, is made up of a combination of buprenorphine and naloxone. 
Prior research by Welsh, Sherman & Tobin (2008) has demonstrated that when taken 
sublingually, Suboxone may be used to reverse an opioid overdose. Since naloxone activity 
is diminished when administered sublingually, it is believed that this effect of Suboxone is 
mediated exclusively through the ability of the buprenorphine component to bind to the 
MOP receptor with high affinity and displace other opioids at this receptor (Welsh, 
Sherman, & Tobin, 2008). However, another case study has demonstrated that when taken 
intravenously, Suboxone is effective in overdose reversal primarily through the naloxone 
component (Yokell, Zaller, Green, McKenzie, & Rich, 2012).  Nevertheless, given the 
excellent safety profile and ready availability of naloxone in most U.S. cities, the exclusive 
use of naloxone to diagnose and treat opioid overdose is the standard of care. 
Physician-Patient Concerns About Naloxone 
Naloxone is a prescription medication, and efforts to expand co-prescription as a 
preventative effort for opioid stewardship have been growing.  Most notably, the Centers 
for Disease Control and Prevention (CDC) included the co-prescription of naloxone as one 
of its key recommendations for improving the treatment of chronic pain when prescribing 
opioids. In addition, the Substance Abuse and Mental Health Services Administration 
(SAMHSA) has developed opioid overdose toolkits that have focused on the provision of 
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naloxone in treatment settings and prevention programs for over a decade (Dowell, 
Haegerich, & Chou, 2016; SAMHSA, 2013). Still, there are many factors influencing the 
decisions of both prescribers and patients to discuss the use of naloxone while together in 
a clinical setting. These factors may present as barriers to a potentially life-saving 
prescription and thus they are worth considering.  
Despite the benefits for patients, physicians are still faced with obstacles to 
prescribing naloxone. For instance, in a study conducted by Binswanger et al. (2015), many 
physicians reported “limited awareness and clinical knowledge about outpatient naloxone 
prescribing” (Binswanger et al., 2015). Some physicians also believed that naloxone might 
give patients a “false sense of security”, which could foster increased opioid use. 
Furthermore, some physicians noted that although it seems intuitive to prescribe naloxone, 
there was still some overall discomfort associated with doing so (Binswanger et al., 2015).  
On the other hand, a study by Mueller et al. (2017) investigated attitudes of patients 
with chronic non-cancer pain (CNCP) toward naloxone prescribing and found several 
barriers that influenced their willingness to discuss naloxone with their prescribers. First, 
patients reported having minimal prior education about the risks involved in taking opioid 
medications, and they indicated learning about the risks from friends/family rather than 
from their prescribers (Mueller, Koester, Glanz, Gardner, & Binswanger, 2017). Second, 
if patients reported familiarity with naloxone, it was generally in the context of heroin use 
instead of opioid use for CNCP. Third, patients felt they needed to constantly prove to their 
prescribers that they were indeed experiencing pain, and so they were hesitant to inquire 
about naloxone because this could contribute to their prescribers’ perceptions of them as 
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“drug-abusers.” On a similar note, patients reported fear of losing opioid pain therapy as a 
barrier to discussing naloxone with their prescribers (Mueller et al., 2017).  
Pharmacist-Patient Concerns About Naloxone 
Similar to prescriber-patient concerns, there are many factors influencing the 
decisions of both pharmacists and patients to discuss the use of naloxone while in the 
pharmacy. These factors may present as barriers to a potentially life-saving prescription, 
and therefore they are worth considering.  
 Among pharmacists who participated in focus groups in a study by Green et al. 
(2017), there was a belief that offering naloxone might negatively impact relationships with 
patients. They reported that patients might feel as though they were being accused of 
something and that bringing up naloxone in general could come across as offensive (Green 
et al., 2017). Some pharmacists also felt they lacked the training to adequately educate 
patients about naloxone and thus were hesitant to do so. A third barrier found among 
pharmacists was centered around billing and insurance. There was confusion about the 
mandate of filling naloxone for the user but not necessarily knowing who the final user 
might be, leading to concerns about insurance fraud. Despite these barriers, all focus groups 
settled on the same solution of universal naloxone offering; that is, offering naloxone to all 
patients who are eligible. This decision was made because it would not only help raise 
awareness about naloxone but also increase patient exposure to the drug (Green et al., 
2017).  
In the same study, Green et al. (2017) reported that fear of being treated poorly by 
pharmacists was a factor influencing patients’ decisions to purchase naloxone from the 
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pharmacy. Moreover, apart from the pharmacy setting, patients were concerned about 
being labeled as an addict by police if found with naloxone (Green et al., 2017).   
Similarities to Other Harm Reduction Provisions in the Pharmacy: Sales of Syringes  
In addition to naloxone provision, the pharmacy is also a critical place of 
distribution for other harm reduction supplies, especially syringes. In the United States, 
people who inject drugs (PWIDs) are able to obtain sterile syringes from syringe exchange 
programs (SEPs) or, in some states, without a prescription from their local pharmacy. SEPs 
have continued to provide clean syringes, harm reduction counseling, and referrals to social 
service programs for countless people for decades. The sale of non-prescription syringes 
at a pharmacy is currently legal in 46 states, including Massachusetts (Zaller, Yokell, 
Apeakorang, Gaggin, & Case, 2012).  
Syringe sales in the pharmacy can be a useful tool when investigating the 
technicians’ perspectives on their patient population’s use of street drugs. This was 
demonstrated in a study by Zaller et al. (2012) which reported that pharmacy staff could 
distinguish PWIDs from other individuals based on stereotypical appearances or behaviors 
(Zaller et al., 2012).  This shows that technicians can provide insight into approximately 
what percentage of their patients inject drugs, and so researchers can then determine their 
stance on naloxone by asking them what percentage of patients could benefit from 
naloxone. By asking these questions, one can better understand the technicians’ 
perspectives about naloxone and also determine whether there is a correlation between 
syringe and naloxone sales. 
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Pharmacy Technicians and Their Potential for Impact on Public Health 
Pharmacy technicians are an integral component of the pharmacy environment. 
They work under the supervision of a pharmacist in both retail and hospital pharmacies, 
and traditionally their roles have been to process and fill prescriptions, maintain and record 
drug inventories, and coordinate the billing of medications between the patients and third-
party insurance providers. By completing these tasks, technicians allow pharmacists to 
spend more time focused on patient care (Maine, Knapp, & Scheckelhoff, 2013).  
In recent years, however, the roles of pharmacy technicians have been rapidly 
expanding. For instance, technicians have begun to play an active role in the delivery of 
pharmacy-based immunization programs. Prior research has shown that the involvement 
of technicians in immunization programs can help facilitate the delivery of vaccines. This 
can be done by alleviating some of the logistic obstacles involved in vaccination such as 
documentation, billing, and reporting adverse reactions, thereby resulting in an increased 
administration of vaccines (Burson, Buttenheim, Armstrong, & Feemster, 2016; Powers & 
Hohmeier, 2011). Further evidence of the impact of technicians on vaccination rates was 
seen in a pilot program conducted by Hill et al. (2017), which investigated pharmacy 
technician interventions on vaccine rates. In this study, technicians identified patients who 
were not previously screened or immunized for influenza, and then followed up with 
nursing staff through phone calls or in-person discussions. This resulted in a statistically 
significant increase in the influenza vaccine administration rate compared with control 
groups having no technician intervention (Hill, Anderegg, & Couldry, 2017). In the past 
year, Idaho took technician responsibilities one step further by becoming the first state to 
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permit technicians to administer vaccines under the supervision of a pharmacist (Bright & 
Adams, 2017). Follow-up studies involving Idaho technicians demonstrated that trained 
technicians are knowledgeable about the procedures involved in vaccination and are 
confident in participating in the process after completing a short training program 
(McKeirnan, Frazier, Nguyen, & MacLean, 2018).  
Given this data, it is not surprising that the role of pharmacy technicians is being 
studied as having a large potential for impact on public health. Higher vaccination rates are 
one example of the efficacy of using the technician role to enhance public health measures. 
With regard to the opioid epidemic, there is little known about the role of pharmacy 
technicians in improving public health outcomes, and therefore this is an area of research 
that warrants investigation.  
Objectives of the Research Study 
Prior research on the topic of attitudes toward naloxone prescriptions and 
dispensing has focused primarily on three groups of people: (1) patients actively using 
illicit opioid drugs, opioid consumers in recovery, or patients living with chronic pain who 
have been prescribed opioid analgesics; (2) licensed physicians/prescribers who prescribe 
naloxone for patients; and (3) licensed pharmacists who dispense naloxone or have training 
in this drug. Therefore, there is a lack of research centered on the role of pharmacy 
technicians in the dispensing of naloxone. In a pharmacy setting, it is not uncommon for 
the pharmacist to be quite busy with many activities, including checking medications and 
administering flu shots. As a result, the first interaction a patient has with a pharmacy staff 
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member is often with a pharmacy technician. From dropping off a prescription to picking 
up medications, patients are constantly interacting with pharmacy technicians.   
The aim of this study is to investigate the attitudes and perceptions of pharmacy 
technicians in the dispensing of naloxone in a selection of pharmacies across 
Massachusetts. This aim is accomplished by administering a survey to pharmacy 
technicians in 39 CVS pharmacies, and the analysis of the responses seeks to understand 
the thoughts of these technicians. Some areas of particular interest include determining if 
the technicians (1) consider certain groups to be more at risk of overdose than others, (2) 
have different attitudes and perceptions depending on whether the opioid-related overdose 
death rate for their town is greater or less than the state average, and (3) believe those 
purchasing syringes for street use could benefit the greatest from naloxone.  
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METHODS 
 
 This study employed survey administration as the primary means for data 
collection. In total, 39 CVS pharmacies across Massachusetts were visited, resulting in data 
collected from 39 pharmacy technicians. Based on the report published by The 
Commonwealth of Massachusetts entitled “An Assessment of Fatal and Nonfatal Opioid 
Overdoses in Massachusetts (2011-2015),” which includes data from 348 municipalities 
across Massachusetts, the state average annual opioid-related death rate per 100,000 people 
from 2011 to 2015 was calculated to be 12.2 (Massachusetts Registry of Vital Records and 
Statistics. Massachusetts Department of Public Health, 2017). Any municipality with a rate 
below this number was classified as being at low risk of opioid overdose, and any 
municipality with a rate greater than or equal to this number was classified as being at high 
risk of opioid overdose. Of the 39 CVS pharmacies visited for this study, 21 were from 
High-Risk Municipalities (HRM) and 18 were from Low-Risk Municipalities (LRM). 
These stores were purposively sampled to ensure geographical variability among the state 
as well as to mitigate influences from neighboring municipalities which may have different 
rates. In all cases, the pharmacist on duty was introduced to the study and asked permission 
to speak to a lead technician, if available. All stores were visited between Monday and 
Friday from the hours of 9:00 a.m. to 5:00 p.m. EST. Pharmacies were not visited outside 
of this timeframe in order to mitigate the chance of speaking with a part-time technician or 
a relief technician. As CVS was a research partner in the parent study, only CVS 
pharmacies were included in this study.  The study was approved by the Boston Medical 
Center Institutional Review Board (BMC IRB).  
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Selection Criteria for High-Risk CVS Pharmacies 
 A total of 168 municipalities were identified as being at high risk of opioid overdose 
(i.e., having an annual opioid-related death rate per 100,000 people ≥ 12.2) (Massachusetts 
Registry of Vital Records and Statistics. Massachusetts Department of Public Health, 
2017). From these 168 municipalities, 7 were purposively sampled to obtain geographic 
variability across the state and were thus designated HRM. Three stores were then surveyed 
per municipality, regardless of size, so as to ensure equal representation. Inclusion criteria 
consisted of having 3 or more CVS pharmacies in that municipality, as well as using 
Massachusetts geography to include municipalities in areas such as North Shore and South 
Shore. This was done to allow for a wide range of data that could more accurately represent 
each municipality and Massachusetts as a whole. Overall, 7 HRM were visited, with 3 
stores per municipality, resulting in a total of 21 high-risk stores being included in the 
survey.  
Selection Criteria for Low-Risk CVS Pharmacies 
 A total of 180 municipalities were identified as being at low risk of opioid overdose 
(i.e., having an annual opioid-related death rate per 100,000 people < 12.2) (Massachusetts 
Registry of Vital Records and Statistics. Massachusetts Department of Public Health, 
2017). From these 180 municipalities, 6 were purposively sampled based on fulfillment of 
the eligibility criteria and were designated LRM. Three stores were then surveyed per 
municipality, regardless of size, so as to ensure equal representation. Similar to high-risk 
pharmacies, inclusion criteria consisted of having 3 or more CVS pharmacies in that 
municipality. Exclusion criteria for LRM included shared borders with HRM, mainly 
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because residents/patients from the HRM might also visit CVS pharmacies in the 
neighboring LRM, thus skewing the data collected from those stores. Overall, 6 Low-Risk 
Municipalities (LRM) were visited, with 3 stores per municipality, resulting in a total of 
18 low-risk stores being included in the survey.  
Visual Representation of High-Risk and Low-Risk CVS Pharmacies 
 Figure 5 depicts the state of Massachusetts, outlined in red, with markers for each 
of the various pharmacies visited for the survey (Google, n.d.). The blue markers represent 
high-risk stores, and the red markers represent low-risk stores. Figure 6 is a magnified view 
of the map in Figure 5, allowing for a more detailed visualization of the stores and 
municipalities that were visited (Google, n.d.). As in Figure 5, the blue markers represent 
high-risk stores, whereas the red markers represent low-risk stores. The high-risk stores 
have been labelled A through G, and the low-risk stores have been labelled 1 through 6. 
Table 1 correlates these letters to the specific high-risk municipalities that were visited. 
Table 2 correlates these numbers to the specific low-risk municipalities that were visited. 
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Figure 5. Locations of high-risk stores and low-risk stores visited for the survey. This 
figure shows a geographical representation of the state of Massachusetts (outlined in red) 
as well as the locations of high-risk stores (blue) and low-risk stores (red). Additional, 
detailed information can be found in Figure 6 and Tables 1 and 2. Retrieved from (Google, 
n.d.). 
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Figure 6. A magnified view of Figure 5 showing the locations of high-risk stores and 
low-risk stores visited for the survey. This figure shows a close-up of Massachusetts with 
the locations of high-risk stores (blue; A-G) and low-risk stores (red; 1-6). Refer to Tables 
1 and 2 for the corresponding municipalities for each letter and number. Retrieved from 
(Google, n.d.). 
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Table 1. High-Risk Municipality (HRM) Pharmacies in Massachusetts.1 
Letter 
Designation 
in Figure 6 
Municipality 
A Salem 
B Malden 
C Medford 
D Worcester 
E Brockton 
F Taunton 
G Plymouth 
 
 
Table 2. Low-Risk Municipality (LRM) Pharmacies in Massachusetts.2  
Number 
Designation 
in Figure 6 
Municipality 
1 Framingham 
2 Wellesley 
3 Newton 
4 Brookline 
5 Dedham 
6 Milford 
 
 
                                                      
1 This table lists the 7 HRM visited for the survey as well as their corresponding letter 
designation in Figure 6 
2 This table lists the 6 LRM visited for the survey, as well as their corresponding letter 
designation in Figure 6 
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Survey Design 
 Figure 7 depicts the survey used for both high-risk and low-risk pharmacies. 
Questions 1 through 4 were adapted from the 2017 Pharmacists Survey from the MOON 
Study at BMC. Similarly, questions 18 through 22 were taken from the 2017 Pharmacists 
Survey from the MOON Study at BMC. This resource was used to collect data which can 
also be utilized for future research directed at comparing pharmacist and pharmacy 
technician perspectives on patient populations. Questions 23 through 45 were included in 
the survey in order to collect data to be used in future research surrounding the 
effectiveness of the MOON Study naloxone literature and the patterns of syringe sales. 
Therefore, these questions were not included in the analysis. Questions 39 through 45 
(pertaining specifically to syringes) were only asked at low-risk stores and select high-risk 
stores, because other researchers at BMC previously collected these data from the 
remaining high-risk stores. Furthermore, under the “Additional Feedback” section, extra 
comments and feedback related to the discussed topics were recorded.  
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Figure 7. The survey that was used to collect data from Massachusetts pharmacy 
technicians in HRM and LRM. 
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Figure 7. The survey that was used to collect data from Massachusetts pharmacy 
technicians in HRM and LRM. (Continued) 
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Figure 7. The survey that was used to collect data from Massachusetts pharmacy 
technicians in HRM and LRM. (Continued) 
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Figure 7. The survey that was used to collect data from Massachusetts pharmacy 
technicians in HRM and LRM. (Continued) 
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Figure 7. The survey that was used to collect data from Massachusetts pharmacy 
technicians in HRM and LRM. (Continued) 
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Figure 7. The survey that was used to collect data from Massachusetts pharmacy 
technicians in HRM and LRM. (Continued) 
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Survey Administration 
 Most surveys were completed by the investigator (Shawn Kurian) at the pharmacy 
counseling counter, although a small number were completed by the investigator at the 
patient waiting area or the employee lunch room. Prior to beginning the survey, all 
participants were informed that their answers would remain anonymous and that no 
personal or identifying information would be collected from them. The questions were 
verbally read aloud followed by the response options, and the participants were asked to 
select the appropriate answer choice.  
Clarification was given for the fourth response in question 10 (“Pharmacists 
counsel patients on naloxone” as a response to “How do patients learn about or obtain 
naloxone in the pharmacy?”). After being read the fourth response, participants were given 
the following example: if a pharmacist notices a patient is taking multiple opioid 
medications or taking them with benzodiazepines, the pharmacist would then approach the 
patient and counsel/educate them on naloxone and its potential benefits.  
Clarification was also given for question 22 (“If encouraged to do so from a 
pharmacist, what is the likelihood that you would say this to a pharmacy patient?” with the 
quote being “The pharmacists here are recommending that everyone picking up these 
medications get naloxone in case of a breathing emergency. Is that something you would 
like to talk to the pharmacist about today?”). After being read the question, participants 
were told that in this hypothetical scenario their use of the quote would not impact their 
job performance in any way; they would not be rewarded if they said the quote or penalized 
if they did not.  
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Statistical Analyses 
 IBM SPSS Statistics was used to statistically analyze the data for levels of 
significance. Because of the ordinal nature of the data, a series of Mann-Whitney U and 
Chi-Square Test of Independence tests were performed. The independent variable in each 
case was the level of risk in the municipality (i.e., high-risk or low-risk). The dependent 
variables were the responses to the survey questions.   
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RESULTS 
 
An in-person survey was successfully administered to 39 Massachusetts pharmacy 
technicians (Table 3), with both a response rate and a completion rate of 100%. Question 
9 on the survey was excluded from analysis because zero participants selected “yes” to 
“Has this pharmacy ever denied a customer the purchase of naloxone? If yes, why?” 
The results of this experiment (Table 4) demonstrate that there was no significant 
difference between the participant responses in LRM and HRM pharmacies to questions 5 
through 19 as well as questions 21 and 22. These questions pertained to the dispensing 
frequency of naloxone, how patients learn about or obtain naloxone, positive attitudes 
toward naloxone dispensing, ease of identifying at-risk patients, and likelihood of asking 
patients if they would like to speak to the pharmacist about naloxone. However, for 
question 20 (“Approximately what percent of patients do you think could benefit from 
having a naloxone kit available?”), the Mann-Whitney U significance level was 0.001 for 
results in which 67% of participants in LRM indicated that less than 25% of patients could 
benefit from having a naloxone kit available and 67% of participants in HRM indicated 
that greater than 50% of patients could benefit. This demonstrates that there is a significant 
difference in perception among pharmacy technicians in LRM and HRM about the 
approximate percentage of patients who could benefit from having a naloxone kit available. 
This result is important to consider because there was no significant difference observed 
for questions 18 and 19, which measured the approximate percentage of patients who the 
technician believed used illicit opioids or currently had prescription opioids prescribed to 
them.  
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Although the results for question 21 (“Which of the following patients at risk of 
overdose are the easiest to identify? [Please select the two you feel are easiest to identify 
and will yield the most benefit for receiving naloxone to take home]”) were not 
significantly different across HRM and LRM groups, approximately the same percentage 
of participants in both groups selected all of the responses except for two. First, the 
percentage of participants in the LRM who selected “Patients receiving prescriptions for 
both opioids and benzodiazepine medications” was nearly double the percentage of 
participants in the HRM who selected this option. Second, the percentage of participants 
in the HRM who selected “Patients purchasing syringes over the counter” was nearly 20% 
greater than the percentage of participants who selected this in the LRM.  
 Similarly, although the results for question 22 (“‘The pharmacists here are 
recommending that everyone picking up these medications get naloxone in case of a 
breathing emergency. Is that something you would like to talk to the pharmacist about 
today?’... If encouraged to do so from a pharmacist, what is the likelihood that you would 
say this to a pharmacy patient?”) were not significantly different across HRM and LRM 
groups, it is clear that technicians working in both HRM and LRM pharmacies are 
generally more willing than not to use this language in the pharmacy setting. To highlight 
this point, the responses for “Extremely Unlikely” to “Neither Likely nor Unlikely” were 
collapsed and the responses for “Slightly Likely” to “Extremely Likely” were collapsed.   
Additional Comments/Feedback from Participants Regarding Survey Topics 
Additional, unsolicited comments and feedback from the HRM revealed many 
common themes. First, two technicians stated they could not provide an answer for 
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question 11 (“I am comfortable answering patient questions about naloxone”) because they 
insisted that they “must refer [patients] to the pharmacist” when asked any questions about 
medications. Thus, their responses were recorded as “N/A.” Two other technicians cited 
the CVS policy that they are not allowed to answer questions about medications, yet they 
selected “Neither Agree nor Disagree” and “Strongly Disagree.” In order to accurately 
reflect these comments, these two responses were changed to “N/A,” yielding a total of 
four “N/A” responses for question 11 in HRM.   
Second, two HRM technicians expressed their beliefs that patients use naloxone 
but return to misusing opioids afterward. One technician noted that “people take advantage 
of naloxone and continue to overdose,” whereas the other technician claimed that patients 
believe it is a “magic fix” and that “after using naloxone patients will return back to using 
drugs.”   
Third, three technicians reported that if individuals ask about naloxone it is 
typically for a loved one or, because they know people who overdosed, for themselves as 
a measure of caution. Specifically, the first technician mentioned that “one patient got 
naloxone for themselves after their father overdosed” and another patient was “asking for 
[naloxone for] their sister.” The second technician commented that “most people getting 
[naloxone] have overdosed or have friends who overdosed. So, it’s first-hand experience.” 
The third technician noted that “only one or two patients ask for [naloxone] and it’s for a 
loved one.”  
Regarding costs, one technician stated that naloxone is “too expensive for all 
patients” and “patients are unwilling to pay out of pocket [for naloxone].” On the topic of 
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syringes, one technician stated that they “would like the right to refuse to sell syringes to 
certain people when it’s evident they’re under the influence of other drugs.”  
As seen in Table 4, in response to question 20 (“Approximately what percent of 
patients do you think could benefit from having a naloxone kit available?”), the majority 
of HRM reported that over 50% of patients could benefit, with three technicians (14%) 
reporting that 10%-25% could benefit. Interestingly, one of the technicians who selected 
10%-25% commented that “most patients are responsible,” and another technician who 
selected this range noted that “patients with prescriptions are not at risk” and thus gave the 
same response previously given for question 18 (“Approximately what percent of patients 
do you think use illicit opioids [i.e. heroin, fentanyl, diverted prescription medications]?”). 
Moreover, in response to the quote in question 22 (“‘The pharmacists here are 
recommending that everyone picking up these medications get naloxone in case of a 
breathing emergency. Is that something you would like to talk to the pharmacist about 
today?’... If encouraged to do so from a pharmacist, what is the likelihood that you would 
say this to a pharmacy patient?”), one technician chose “Moderately Unlikely” because 
they believed “customers would freak out” if they heard that from the technician. Only one 
technician in HRM mentioned that there is a protocol for dispensing naloxone directly from 
CVS. 
 In addition, unsolicited comments and feedback were obtained from the LRM, 
which revealed many common themes among pharmacy technicians. First, consistent with 
the pharmacy technician’s comments in the HRM, one technician stated an inability to 
provide an answer for question 11 (“I am comfortable answering patient questions about 
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naloxone”) because management does not allow answering questions about medications. 
Thus, the response for this question was “N/A.” 
Second, two technicians mentioned that physicians should provide prescriptions for 
naloxone along with prescriptions for pain medications because this would alleviate some 
tensions faced by staff members. Specifically, the first technician stated that “doctors 
should [prescribe naloxone] with prescriptions too” and “[doctors should] show patients 
how to use [naloxone].” The same technician noted that they “find it difficult to [discuss 
naloxone as they are worried about] crossing the line.” They also said that “patients might 
find it offensive if [technicians bring up naloxone] if they [are taking] pain medications 
due to a car accident.” The second technician stated that co-prescribing is important 
because “when the pharmacist brings up naloxone the patient might become offended.” 
Third, two technicians believed that patients may be misinformed about the 
potential uses of naloxone. In particular, one technician stated that, in general, “the 
patients’ perception is that they’re not a drug addict and therefore they don’t think they 
need naloxone… even though they have opioid prescriptions.” The other technician said 
that “not everyone is knowledgeable about why naloxone is useful” and “[the belief is that] 
only people shooting up on the street need it.”  
Similar to the HRM pharmacy technicians, two participants brought up the issue of 
cost. One stated that “insurance is the primary factor affecting patient decisions to purchase 
[naloxone]” and “parents would buy [naloxone] for their children if it was not so 
expensive.” The other noted that “patients refuse to purchase naloxone due to cost and 
insurance issues.”   
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On the topic of syringes, one technician, who was surveyed in the secluded patient 
waiting area, mentioned that the technicians are willing to dispense clean needles, 
regardless of patient appearance; however, the pharmacy manager often chooses to deny 
patients who fit a certain stereotype. Specifically, these included young patients with 
“blood shot eyes, long sleeves, and asking for syringes for grandma’s diabetes.”  
As seen in Table 4, in response to question 6 (“In the past year, approximately how 
often has this pharmacy dispensed naloxone?”), two LRM technicians selected “Always 
(at least every other day).” Despite this answer, one of these technicians mentioned that 
there are several independent medical practices around the area and that there are many 
naloxone referrals from them. Finally, in reference to the opioid epidemic overall, one 
technician said that it is a “sad state of affairs that we need naloxone.” 
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Table 3. Sample Characteristics of Participants in Survey of Massachusetts 
Pharmacy Technicians.3  
 
 HRM 
n (%) 
nt = 21 
LRM 
n (%) 
nt = 18 
Row 
N 
nt = 39 
Pharmacy Technician Characteristics     
Gender Male 2 (10) 1 (6) 3 
 Female 19 (90) 17 (94) 36 
 Other 0 0 0 
Age, years 18-21 1 (5) 0 1 
 22-25 4 (19) 5 (28) 9 
 26-34 9 (43) 6 (33) 16 
 35-44 4 (19) 3 (17) 7 
 45-64 3 (14) 4 (22) 7 
 65+ 0 0 0 
Racial Identity White/Caucasian 13 (62) 11 (61) 24 
Black/African-American 2 (10) 2 (11) 4 
Asian 0 1 (6) 1 
Native Hawaiian/Pacific 
Islander 
0 0 0 
American Indian/Alaska 
Native 
0 0 0 
Hispanic 3 (14) 3 (16) 6 
More than one race4 3 (14) 0 3 
Other5 0 1 (6) 1 
Length of 
Experience at that 
particular 
pharmacy, years 
0-1 7 (33) 4 (22) 11 
2-3 3 (14) 5 (28) 8 
4-5 6 (29) 3 (17) 9 
6-7 0 2 (11) 2 
8-10 0 2 (11) 2 
11+ 5 (24) 2 (11) 7 
 
 
 
 
                                                      
3 This table shows the number (n) and percentage (%) of pharmacy technicians who had the demographic 
characteristic listed on the left, separated into High-Risk Municipalities (HRM) and Low-Risk 
Municipalities (LRM). nt = total number of participants in each municipality; Row N = total number of 
participants in each row 
4 ‘More than one race” was characterized as “White/Caucasian + Black/African-American” by two 
participants in the HRM and “Black/African-American + Hispanic” by remaining participant in the HRM  
5 ‘Other’ was characterized as “Sinhalese” by the participant in the LRM 
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Table 4. Participant Responses to Survey Questions Under the Subheading “Naloxone 
in the Pharmacy”.6  
 
 HRM  
n (%) 
nt = 21 
LRM  
n (%) 
nt = 18 
Chi-Square 
Test of 
Independence 
“Naloxone in the Pharmacy” Questions     
5. Are you aware that 
naloxone can be used as a 
medication to treat opioid 
overdose? 
Yes 
21 
(100%) 
17 (94%) 
0.274 
No 0 1 (6%) 
 
Mann-
Whitney U 
Significance 
Level 
6. In the past year, 
approximately how often 
has this pharmacy dispensed 
naloxone? 
Never 0 3 (17%) 
0.614 
Rarely (a few times 
per year) 
9 (43%) 6 (33%) 
Sometimes (once per 
month) 
8 (38%) 5 (28%) 
Often (once per 
week) 
4 (19%) 2 (11%) 
Always (at least 
every other day) 
0 2 (11%) 
 
Chi-Square 
Test of 
Independence 
7. Have you ever suggested 
to a patient who might be at 
risk of overdose that they 
get naloxone at the 
pharmacy to take home with 
them? 
Yes 2 (10%) 0 
0.179 
No 19 (90%) 
18 
(100%) 
8. Has this pharmacy ever 
denied a customer the 
purchase of naloxone? If 
yes, why? 
Yes 0 0 
0.847 
Yes; due to stocking 
issues 
4 (19%) 3 (17%) 
No 17 (81%) 15 (83%) 
 
                                                      
6 This table summarizes the responses of pharmacy technicians to the survey questions under the 
subheading “Naloxone in the Pharmacy,” recorded from pharmacies in both High-Risk Municipalities 
(HRM) and Low-Risk Municipalities (LRM) 
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Table 4. Participant Responses to Survey Questions Under the Subheading “Naloxone 
in the Pharmacy”.7 (Continued) 
 
 HRM  
n (%) 
LRM  
n (%) 
Chi-Square 
Test of 
Independence 
“Naloxone in the Pharmacy” Questions    
10. How do patients learn 
about or obtain naloxone in 
this pharmacy?8  
Technicians are the first 
to talk about naloxone 
0 0 
0.535 
Patients are the first to 
inquire about naloxone 
18 (86%) 
11 
(61%) 
Physicians prescribe 
naloxone for patients 
16 (76%) 
8 
(44%) 
Pharmacists counsel 
patients on naloxone 
8 (38%) 
8 
(44%) 
Patients are referred to 
the pharmacy by a 
Treatment Center 
11 (52%) 
8 
(44%) 
Patients are referred to 
the pharmacy by a 
Community Organization 
7 (33%) 
2 
(11%) 
Other: Bystanders 
witness patient 
overdosing in parking lot 
and request naloxone 
1 (5%) 0 
Other: MOON Study 
Literature around the 
pharmacy 
3 (14%) 0 
Other: Friends/family 
ask about naloxone for 
patients 
1 (5%) 0 
Other: Fire 
department/EMS has 
emergency situation 
0 
1 
(6%) 
 
 
 
 
 
                                                      
7 This table summarizes the responses of pharmacy technicians to the survey questions under the 
subheading “Naloxone in the Pharmacy,” recorded from pharmacies in both High-Risk Municipalities 
(HRM) and Low-Risk Municipalities (LRM) 
8 Categories are not mutually exclusive 
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Table 4. Participant Responses to Survey Questions Under the Subheading “Naloxone 
in the Pharmacy”.9 (Continued) 
 
 HRM  
n (%) 
nt = 21 
LRM  
n (%) 
nt = 18 
Mann-
Whitney U 
Significance 
Level 
“Naloxone in the Pharmacy” Questions    
11. I am comfortable 
answering patient 
questions about 
naloxone. 
Strongly Disagree 1 (5) 1 (6) 
0.597 
Disagree 2 (10) 2 (11) 
Somewhat Disagree 1 (5) 0 
Neither Agree nor Disagree 2 (10) 2 (11) 
Somewhat Agree 3 (13) 2 (11) 
Agree 4 (19) 5 (28) 
Strongly Agree 4 (19) 5 (28) 
N/A 4 (19) 1 (6) 
12. I am familiar with 
naloxone and its role in 
reducing overdose risk in 
communities. 
Strongly Disagree 0 1 (6) 
0.517 
Disagree 0 0 
Somewhat Disagree 1 (5) 0 
Neither Agree nor Disagree 1 (5) 0 
Somewhat Agree 3 (14) 4 (22) 
Agree 5 (24) 6 (33) 
Strongly Agree 11 (52) 7 (39) 
13. I am willing to 
participate in the 
dispensing of naloxone 
in this pharmacy. 
Strongly Disagree 0 0 
0.319 
Disagree 0 1 (6) 
Somewhat Disagree 0 0 
Neither Agree nor Disagree 0 1 (6) 
Somewhat Agree 2 (10) 0 
Agree 4 (19) 6 (33) 
Strongly Agree 15 (71) 10 (55) 
14. I am comfortable 
participating in the 
dispensing of naloxone 
in this pharmacy. 
Strongly Disagree 0 0 
0.219 
Disagree 0 1 (6) 
Somewhat Disagree 0 1 (6) 
Neither Agree nor Disagree 0 0 
Somewhat Agree 2 (10) 2 (11) 
Agree 5 (24) 5 (28) 
Strongly Agree 14 (67) 9 (50) 
 
                                                      
9 This table summarizes the responses of pharmacy technicians to the survey questions under the 
subheading “Naloxone in the Pharmacy,” recorded from pharmacies in both High-Risk Municipalities 
(HRM) and Low-Risk Municipalities (LRM) 
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Table 4. Participant Responses to Survey Questions Under the Subheading “Naloxone 
in the Pharmacy”.10 (Continued) 
 
 HRM  
n (%) 
nt = 21 
LRM  
n (%) 
nt = 18 
Mann-
Whitney U 
Significance 
Level 
“Naloxone in the Pharmacy” Questions    
15. I am willing to learn 
more about naloxone and 
how it can be used in this 
pharmacy. 
Strongly Disagree 0 0 
0.351 
Disagree 0 1 (6) 
Somewhat Disagree 0 0 
Neither Agree nor Disagree 1 (5) 0 
Somewhat Agree 1 (5) 0 
Agree 7 (33) 4 (22) 
Strongly Agree 12 (57) 13 (72) 
N/A 0 0 
16. It is good that 
naloxone is available to 
people in Massachusetts 
by standing order. 
Strongly Disagree 0 0 
0.894 
Disagree 0 0 
Somewhat Disagree 0 0 
Neither Agree nor Disagree 2 (10) 1 (6) 
Somewhat Agree 1 (5) 0 
Agree 4 (19) 6 (33) 
Strongly Agree 14 (67) 11 (61) 
N/A 0 0 
17. The people who 
would benefit most from 
naloxone are those 
purchasing syringes for 
drug use.  
Strongly Disagree 1 (5) 0 
0.095 
Disagree 1 (5) 1 (6) 
Somewhat Disagree 0 1 (6) 
Neither Agree nor Disagree 2 (10) 4 (22) 
Somewhat Agree 2 (10) 4 (22) 
Agree 5 (24) 5 (28) 
Strongly Agree 9 (43) 3 (17) 
N/A 1 (5) 0 
 
 
 
 
 
                                                      
10 This table summarizes the responses of pharmacy technicians to the survey questions under the 
subheading “Naloxone in the Pharmacy,” recorded from pharmacies in both High-Risk Municipalities 
(HRM) and Low-Risk Municipalities (LRM) 
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Table 4. Participant Responses to Survey Questions Under the Subheading “Naloxone 
in the Pharmacy”.11 (Continued) 
 
 HRM  
n (%) 
nt = 21 
LRM  
n (%) 
nt = 18 
Mann-Whitney 
U Significance 
Level 
“Naloxone in the Pharmacy” Questions    
18. Approximately what 
percent of patients do you 
think use illicit opioids (i.e. 
heroin, fentanyl, diverted 
prescription medications)? 
None  0 1 (5%) 
0.138 
Less than 10% 4 (19%) 5 (28%) 
10-25% 6 (29%) 7 (39%) 
26-50% 3 (14%) 1 (5%) 
Greater than 50% 8 (38%) 4 (22%) 
19. Approximately what 
percent of patients 
currently have prescription 
opioids prescribed to 
them? 
None  0 0 
0.557 
Less than 10% 2 (10%) 1 (6%) 
10-25% 2 (10%) 6 (33%) 
26-50% 7 (33%) 3 (17%) 
Greater than 50% 10 (47%) 8 (44%) 
20. Approximately what 
percent of patients do you 
think could benefit from 
having a naloxone kit 
available? 
None  0 0 
0.001 
Less than 10% 1 (5%) 3 (17%) 
10-25% 3 (14%) 9 (50%) 
26-50% 3 (14%) 4 (22%) 
Greater than 50% 14 (67%) 2 (11%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
11 This table summarizes the responses of pharmacy technicians to the survey questions under the 
subheading “Naloxone in the Pharmacy,” recorded from pharmacies in both High-Risk Municipalities 
(HRM) and Low-Risk Municipalities (LRM) 
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Table 4. Participant Responses to Survey Questions Under the Subheading “Naloxone 
in the Pharmacy”.12 (Continued) 
 
 HRM  
n (%) 
LRM  
n (%) 
Chi-Square 
Test of 
Independence 
“Naloxone in the Pharmacy” Questions    
21. Which of the following 
patients at risk of overdose 
are the easiest to identify? 
(Please select the two you 
feel are easiest to identify 
and will yield the most 
benefit for receiving 
naloxone to take home)13 
 
Patients receiving high 
doses of opioid 
medications 
12 
(57%) 
10 
(56%) 
0.810 
Patients receiving 
prescriptions for both 
opioids and 
benzodiazepine 
medications 
4 
(19%) 
7 
(39%) 
Patients receiving 
opioids with a 28-day or 
more supply 
4 
(19%) 
4 
(22%) 
Patients receiving 
prescriptions for 
buprenorphine/naloxone  
8 
(38%) 
7 
(39%) 
Patients purchasing 
syringes over the counter 
 
14 
(67%) 
8 
(44%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
12 This table summarizes the responses of pharmacy technicians to the survey questions under the 
subheading “Naloxone in the Pharmacy,” recorded from pharmacies in both High-Risk Municipalities 
(HRM) and Low-Risk Municipalities (LRM) 
13 Categories are not mutually exclusive  
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Table 4. Participant Responses to Survey Questions Under the Subheading “Naloxone 
in the Pharmacy”.14 (Continued) 
 
 HRM  
n (%) 
nt = 21 
LRM  
n (%) 
nt = 18 
Mann-
Whitney U 
Significance 
Level 
“Naloxone in the Pharmacy” Questions    
22. This is the language we suggest 
pharmacy technicians use with patients: 
“The pharmacists here are 
recommending that everyone picking up 
these medications get naloxone in case 
of a breathing emergency. Is that 
something you would like to talk to the 
pharmacist about today?” 
 
If encouraged to do so from a 
pharmacist, what is the likelihood that 
you would say this to a pharmacy 
patient? 
Extremely 
Unlikely to 
Neither 
Likely nor 
Unlikely 
9 (43) 5 (28) 
0.334 
Slightly 
Likely to 
Extremely 
Likely 
 
12 (57) 13 (72) 
 
  
                                                      
14 This table summarizes the responses of pharmacy technicians to the survey questions under the 
subheading “Naloxone in the Pharmacy,” recorded from pharmacies in both High-Risk Municipalities 
(HRM) and Low-Risk Municipalities (LRM) 
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DISCUSSION 
 
The results of this study demonstrate that there is a significant difference in 
perception among pharmacy technicians in LRM and HRM about the approximate 
percentage of patients who could benefit from having a naloxone kit available. Since there 
was no significant difference observed between the two groups for questions 18 and 19 
(which measured the approximate percentage of patients who the technician believed used 
illicit opioids or currently had prescription opioids prescribed to them), this result for 
question 20 shows that pharmacy technicians working in HRM may believe more in the 
benefits of naloxone and be better suited to implement a pharmacy technician-based 
intervention for expanding naloxone access. Regardless, this finding could also be due to 
greater knowledge and awareness about naloxone, mediated in part by previous academic 
detailing visits to the HRM pharmacies by MOON Study members in the past. However, 
since the MOON Study academic detailing visits were conducted within the past two years, 
there were not a large number of participants who were exposed to the materials. 
Nonetheless, it would be beneficial for CVS to introduce a naloxone training program for 
its pharmacy technicians, particularly those working in LRM. Following this 
implementation, one could investigate whether LRM technicians changed their views 
about the number of people who could benefit, thereby confirming that a lack of knowledge 
of the topic contributed to their responses. In addition, this CVS-based naloxone training 
program would be well received by technicians working in both HRM and LRM, 
particularly since the majority of technicians (90% in HRM and 94% in LRM) stated that 
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they “Strongly Agree” and “Agree” with the statement “I am willing to learn more about 
naloxone and how it can be used in this pharmacy.” 
From the additional feedback/comments that were received, important differences 
in roles and responsibilities around overdose prevention are clear. Two technicians in LRM 
pharmacies noted that doctors should co-prescribe naloxone or inform patients about it to 
make the conversations at the pharmacy easier and potentially less offensive for patients. 
However, as mentioned previously, a study by Binswanger et al. (2015) demonstrated that 
many prescribers reported “limited awareness and clinical knowledge about outpatient 
naloxone prescribing.” This discrepancy in who should and could be discussing overdose 
prevention and naloxone provision may require greater clarity from professional 
organizations as well as medical and pharmacy leaders. In addition, some prescribers 
demonstrated confusion between naloxone for overdose and medications for addiction 
treatment, such as naltrexone (Binswanger et al., 2015). This issue has implications in the 
pharmacy setting as it might be likely that some inexperienced pharmacy technicians 
confused naloxone for naltrexone during the survey administration. This situation occurred 
on one occasion during survey administration of this study, however, it was quickly 
reiterated that the survey was regarding naloxone, not naltrexone. Despite this, co-
prescribing naloxone along with opioid medications could mitigate some of the tension that 
might arise in the pharmacy around naloxone dispensing. Specifically, the concerns raised 
by two technicians in the LRM pharmacies (described in the Results section) were focused 
on potentially offending patients when bringing up naloxone. Therefore, the action of a 
physician co-prescribing naloxone with opioids could help educate patients about the 
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benefits of naloxone and reduce some of the concerns presented by LRM pharmacy staff 
members about potentially offending patients.  
Moreover, this idea of co-prescribing has implications outside the pharmacy setting 
and on the opioid overdose risk as a whole. For example, co-prescribing of naloxone with 
opioids was proved to be effective during Project Lazarus in rural North Carolina, which 
noted a stark decrease in the opioid overdose death rate in that county from 46.6 per 
100,000 people in 2009 to 29.0 per 100,000 people in 2010 (Albert et al., 2011). Therefore, 
it would be advantageous for prescribers to co-prescribe naloxone with opioid medications 
because this could have implications on pharmacy technician-patient interactions as well 
as on the opioid overdose risk as a whole. Based on the responses to question 21 (“Which 
of the following patients at risk of overdose are the easiest to identify? [Please select the 
two you feel are easiest to identify and will yield the most benefit for receiving naloxone 
to take home]”), it is possible that LRM pharmacies may benefit more from co-prescribing 
than HRM pharmacies since nearly twice the percentage of LRM technicians selected 
“Patients receiving prescriptions for both opioids and benzodiazepine medications” 
compared with HRM technicians. Furthermore, since nearly 20% more HRM technicians 
selected “Patients purchasing syringes over the counter” compared with LRM technicians, 
it is possible that HRM pharmacies require a different strategy for naloxone dispensing 
focused on syringe/illicit use of opioids rather than co-prescribing. Thus, although the idea 
of co-prescribing was not directly investigated in this study, it would be useful for future 
studies to determine if this same belief is shared among all LRM technicians and to contrast 
this result with beliefs of HRM technicians. 
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Another common theme observed in both HRM and LRM pharmacies is the belief 
that individuals taking prescription opioid medications are not at risk of overdose. This 
view was explicitly expressed by one technician working in an HRM, whereas another 
claimed that most patients taking prescription opioids are responsible and therefore do not 
require naloxone. On the other hand, one technician working in an LRM noted that patients 
may be under the impression that they do not require naloxone if they are taking 
prescription opioids, particularly since naloxone is only beneficial for “people shooting up 
[drugs] on the street”. This viewpoint suggests a need for further education about naloxone 
across both technicians and patients. Although naloxone can benefit PWID, it can also 
benefit individuals taking high doses of multiple prescription opioid medications or taking 
them with benzodiazepines. Thus, it is important that both patients and pharmacy staff 
members are made aware of this fact. As previously mentioned, a potential CVS-based 
naloxone training program for staff members would be beneficial for raising technician 
awareness. Following this training, CVS could attempt to raise patient awareness by 
hosting an in-store educational event, geared toward having both pharmacists and 
technicians educate patients on the uses of naloxone.  
On the topic of syringes, only two technicians (one from an LRM and one from an 
HRM) shared their unsolicited opinions, which turned out to be quite different viewpoints. 
As already noted, the HRM technician stated that they “would like the right to refuse to 
sell syringes to certain people when it’s evident they’re under the influence of other drugs,” 
whereas the LRM technician stated that they are willing to dispense clean syringes, 
regardless of patient appearance, but the pharmacy manager often chooses to deny patients 
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who fit a certain stereotype. Even though this may seem contrary to what one would expect, 
it is important to note that these technicians may have differed in their years of experience 
at the pharmacy and so may have different levels of awareness about the benefits of 
providing clean syringes to PWID. It would be beneficial for future studies to investigate 
the relationship between technicians’ years of experience in the pharmacy and their 
willingness to dispense clean syringes to PWID. Furthermore, this notion of following the 
pharmacist’s directions despite what the technician might think is observed elsewhere in 
the literature as well. A study by Zaller et al. (2012) found differences in attitudes toward 
selling syringes. Some technicians did not want to have a more formal relationship with 
PWID, whereas others believed it was important to do so. However, those that wished to 
have a more positive relationship with these customers stated that this often depends on the 
beliefs of the pharmacist who is working at the time (Zaller et al., 2012). This is comparable 
to the statement made by the technician in this study who wished the pharmacist was more 
willing to sell syringes to all patients. Therefore, although technicians may wish to invoke 
positive effects in the pharmacy, either by building positive relationships with PWID or 
dispensing clean syringes to PWID, their actions may be limited by the pharmacist on duty. 
This signifies that it is important for pharmacists and technicians to be united in their stance 
regarding public safety and the opioid epidemic.     
One more general theme seen in both HRM and LRM pharmacies is that technicians 
expressed the patients’ views of naloxone being too expensive. One HRM technician and 
two LRM technicians mentioned that patients are unwilling to pay out-of-pocket for 
naloxone. It would be useful to eliminate this issue faced by patients in the pharmacy by 
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exploring whether the Massachusetts state government could fully cover or subsidize the 
cost of naloxone dispensed at all retail pharmacies, regardless of whether the patient has 
coverage through Medicaid. While the cost of naloxone is covered through Medicaid, 
individuals who are without Medicaid or private insurance are forced to pay out-of-pocket. 
Thus, although there are free naloxone kits available throughout the state, distributed in 
part by the Massachusetts Overdose Education and Naloxone Distribution Program, there 
are many more retail pharmacies in Massachusetts than distribution sites, and these 
pharmacies could provide uninsured patients easier access to naloxone. 
Altogether, the results of this study demonstrated that HRM technicians, compared 
with LRM technicians, believe that a greater percentage of their patient population could 
benefit from naloxone. They results also showed that some LRM technicians advocate for 
physicians to co-prescribe naloxone with other opioid medications. Furthermore, both 
HRM and LRM technicians believe that patients could benefit if the cost of naloxone was 
reduced. In addition, data from both groups revealed that technicians and patients may be 
unaware that naloxone can benefit individuals taking prescription opioids rather than just 
PWID.  
Given these results, CVS Pharmacy would benefit from initiating a naloxone 
training program for its pharmacy technicians to raise awareness about the uses of naloxone 
and the various patient groups who could benefit from naloxone. This could be orchestrated 
by a monthly huddle-style meeting involving all pharmacy staff members, where they 
review and discuss relevant topics including syringe and naloxone dispensing, how 
naloxone is different from naltrexone, and the patient groups who are at higher risk of 
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overdose. Patients of CVS would benefit from an in-store educational event where 
pharmacy staff members educate patients about naloxone and how they might be at risk of 
overdose. At the prescriber level, it would be noteworthy to reach out to the media and 
professional organizations such as the Massachusetts Academy of Family Physicians and 
convey the potential benefits of co-prescribing naloxone particularly in LRM. This could 
also encourage physicians to introduce naloxone to their patients and thus mitigate some 
of the tensions faced by pharmacy staff members in the dispensing of naloxone.  
Study Limitations 
As is often the case in research, there are several limitations to this study that may 
have affected the results. First, many pharmacies were quite busy, so the pharmacist 
instructed the technicians to complete the survey quickly. As a result, the technicians may 
have felt pressured during the survey, thus they may not have provided their most accurate 
responses.  
Second, in many pharmacies there were several other staff members working 
alongside the technician, including the pharmacist(s), pharmacy intern(s), student(s), and 
other technicians. In these instances, when the survey was administered at the counseling 
counter, it was very easy for co-workers to overhear the participants’ responses. This factor 
could have affected the responses because participants would be more inclined to provide 
answers that are more socially appeasing. This effect may have been particularly apparent 
in questions 5, 11 through 17, and 22, in which participants were asked to provide 
information about themselves. Similarly, participants may have exhibited participant bias, 
choosing answers that they believed would most benefit the experimenter. Although these 
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factors could have been eliminated if participants were given the survey to complete on 
their own, it would have been at the risk of participants rushing through the survey and not 
taking the time to carefully consider each question.  
Third, the survey did not ask a question to distinguish between technicians who 
work full-time and those who work part-time. This has implications on the results of this 
experiment because those with several years of part-time experience, perhaps working once 
per week, may not have the same knowledge or awareness about naloxone and the patient 
population as someone who worked full-time for the same number of years.  
Future Directions for Research 
There are a few aspects of this study that could be expanded in future experiments. 
It would be very interesting to obtain actual naloxone dispensing numbers from CVS and 
determine if there is a statistically significant difference in the amount of naloxone 
dispensed at LRM and HRM. It would be of further interest to compare these naloxone 
dispensing numbers with actual syringe sales and establish whether there is a correlation 
between the two in both LRM and HRM. An additional aspect for consideration would be 
to account for nonverbal biases while conducting a similar survey, particularly with 
questions involving personal opinions and beliefs. This could be useful in helping to 
mitigate some of the previously mentioned biases.   
 Due to the nature of this survey, data pertaining to the effectiveness of naloxone 
literature and syringe sale patterns were not analyzed. These questions were asked in order 
to collect data that could be used in future experiments. These experiments would be aimed 
at either investigating the willingness of pharmacy staff members to use the literature or 
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examining the correlation of syringe sales with naloxone sales in HRM and LRM. Also, as 
most technicians in both groups answered “No” to question 7 (“Have you ever suggested 
to a patient who might be at risk of overdose that they get naloxone at the pharmacy to take 
home with them”), with many citing CVS policies, it would be interesting to study the 
effects of technician-initiated naloxone discussions on the sales of naloxone and, 
consequently, the opioid-related overdose death rate. Therefore, future studies are 
recommended to analyze these data and to determine whether there are any observable 
patterns in these areas.  
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